Cell Biotech Co., Ltd. (KOSDAQ:049960)

Market Cap	110.60B +28.4%
Revenue (ttm)	53.13B +6.4%
Net Income	10.13B -33.1%
EPS	1,479.00 -33.1%
Shares Out	6.84M
PE Ratio	10.93
Forward PE	n/a
Dividend	600.00 (3.73%)
Ex-Dividend Date	Dec 29, 2025

Volume	12,664
Average Volume	20,928
Open	15,960
Previous Close	15,970
Day's Range	15,870 - 16,200
52-Week Range	11,350 - 16,710
Beta	0.34
RSI	65.58
Earnings Date	May 12, 2026

About Cell Biotech

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 101
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049960

Financial Performance

In 2025, Cell Biotech's revenue was 53.13 billion, an increase of 6.44% compared to the previous year's 49.91 billion. Earnings were 10.13 billion, a decrease of -33.06%.